Jci_page_head_homepage_01 Jci_page_head_homepage_02
Eun Jeong Park, J. Rodrigo Mora, Christopher V. Carman, JianFeng Chen, Yoshiteru Sasaki, Guiying Cheng, Ulrich H. von Andrian, Motomu Shimaoka
Published in Volume 117, Issue 9
J Clin Invest. 2007; 117(9):2526–2538 doi:10.1172/JCI31570
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 3
Expression of integrins and activation markers in β7 (D146A) mice.

(A) Cell surface expression of integrins on WT and β7 (D146A) KI lymphocytes from the SP and from SI-IEL and SI-LPL compartments. (B) Cell surface expression of activation markers on lymphocytes from SP. (C) mRNA expression of β7 integrins in splenocytes. Real-time quantitative RT-PCR was performed by iCycler (Bio-Rad). The mRNA expression of the β7 integrin was normalized to that of GAPDH. Dots represent 3 independent data sets; bars denote mean values. (D) Total (cell surface plus intracellular) protein expression of β7 integrins in splenocytes. Total expression was examined by immunofluorescent flow cytometry using permeabilized cells. (E) Effects of a proteasome inhibitor on the cell surface expression of integrins. WT and KI splenocytes were treated for 8 hours with epoxomicin (0.5 μM) in the presence of PMA (20 nM) and ionomycin (1 μM). Surface expression of αL and β7 integrins was examined by flow cytometry. (F) Effects of CD3/CD28/RA treatment on the expression of cell surface receptors. Splenocytes were stimulated with mAbs to CD3 and CD28 for 2 days and treated for 3 days with RA in the absence of mAb stimulation. (A, B, D, and F) Numbers denote mean fluorescent intensity (MFI). Binding of isotype control antibodies is shown with dashed lines. (E) Numbers denoting MFI values for vehicle-treated (dashed lines) and epoxomicin-treated (solid lines) samples are shown with and without parentheses, respectively.